Published in PLoS One on December 07, 2011
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest (2014) 1.12
Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines (2012) 1.01
17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother (2013) 0.96
Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2012) 0.94
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses (2013) 0.87
Memory B cells form in aged mice despite impaired affinity maturation and germinal center kinetics. Exp Gerontol (2014) 0.83
Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more. Hum Vaccin Immunother (2013) 0.82
Advances and controversies in yellow fever vaccination. Ther Adv Vaccines (2013) 0.80
Serious adverse events associated with yellow fever vaccine. Hum Vaccin Immunother (2015) 0.77
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol (2008) 7.18
Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol (2002) 6.60
Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet (2001) 3.21
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet (2001) 3.09
A simple micro-culture method for the study of group B arboviruses. Bull World Health Organ (1969) 2.75
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis (2008) 2.54
Biology of immune responses to vaccines in elderly persons. Clin Infect Dis (2008) 2.32
Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis (2008) 2.14
Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet (2001) 2.09
Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2010) 2.00
Yellow fever vaccination: how much is enough? Vaccine (2005) 1.89
Adverse event reports following yellow fever vaccination. Vaccine (2008) 1.63
Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol (1973) 1.35
Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine (2005) 1.31
Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol (2006) 1.21
History of thymoma and yellow fever vaccination. Lancet (2004) 1.17
Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine (2007) 1.13
An inactivated cell-culture vaccine against yellow fever. N Engl J Med (2011) 1.13
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine (2010) 1.12
Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg (2007) 1.09
Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg (1999) 1.05
Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J (2005) 1.03
Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin (2005) 1.02
Immunity and ageing in man. Exp Gerontol (2006) 1.01
Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis (2009) 0.97
Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine (2010) 0.95
Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One (2008) 0.93
Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai (2002) 0.90
Global Advisory Committee on Vaccine Safety, 2-3 December 2004. Wkly Epidemiol Rec (2005) 0.81
[Adverse effects of attenuated yellow fever vaccine with multiple organ injury--a case report]. Zhonghua Yi Xue Za Zhi (2005) 0.79
Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914]. Vaccine (2006) 0.79
Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine (2009) 0.79
International laboratory network for yellow fever vaccine-associated adverse events. Vaccine (2008) 0.78
Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol (2003) 9.09
Clostridium difficile infection in Europe: a hospital-based survey. Lancet (2011) 6.25
Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol (2010) 3.71
Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet (2004) 2.90
No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: a randomized, placebo-controlled study. Crit Care Med (2002) 2.79
Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA (2004) 2.60
Heredity versus environment in tuberculosis in twins: the 1950s United Kingdom Prophit Survey Simonds and Comstock revisited. Am J Respir Crit Care Med (2007) 2.30
β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect (2010) 2.25
High-throughput genotyping of Salmonella enterica serovar Typhi allowing geographical assignment of haplotypes and pathotypes within an urban District of Jakarta, Indonesia. J Clin Microbiol (2008) 2.14
Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis (2009) 2.07
Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother (2010) 2.06
Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet (2002) 1.98
Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J Immunol (2008) 1.91
Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis (2004) 1.85
Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis (2002) 1.84
Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis (2007) 1.84
Acute muscular sarcocystosis: an international investigation among ill travelers returning from Tioman Island, Malaysia, 2011-2012. Clin Infect Dis (2014) 1.80
Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J (2010) 1.76
Individual, social, environmental, and physical environmental correlates with physical activity among Canadians: a cross-sectional study. BMC Public Health (2009) 1.68
Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J (2012) 1.68
Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol (2007) 1.59
Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One (2009) 1.56
The smallest capsid protein mediates binding of the essential tegument protein pp150 to stabilize DNA-containing capsids in human cytomegalovirus. PLoS Pathog (2013) 1.54
An RNA pseudoknot is required for production of yellow fever virus subgenomic RNA by the host nuclease XRN1. J Virol (2010) 1.49
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother (2011) 1.49
Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg (2005) 1.49
Extended-spectrum β-lactamase-producing enterobacteriaceae among travelers from the Netherlands. Emerg Infect Dis (2013) 1.47
Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology (2007) 1.44
Nontuberculous mycobacterial cervicofacial lymphadenitis in children from the multicenter, randomized, controlled trial in The Netherlands: relevance of polymorphisms in candidate host immunity genes. Int J Pediatr Otorhinolaryngol (2010) 1.41
Postoperative pro-adrenomedullin levels predict mortality in thoracic surgery patients: comparison with Acute Physiology and Chronic Health Evaluation IV Score*. Crit Care Med (2015) 1.39
Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care (2010) 1.38
Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene (2005) 1.30
Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J Biol Chem (2013) 1.28
A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol (2003) 1.26
The same IkappaBalpha mutation in two related individuals leads to completely different clinical syndromes. J Exp Med (2004) 1.25
Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis (2012) 1.23
Molecular epidemiology of measles viruses in China, 1995-2003. Virol J (2007) 1.20
LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol (2010) 1.20
Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum (2004) 1.20
Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One (2007) 1.19
Maggot excretions/secretions inhibit multiple neutrophil pro-inflammatory responses. Microbes Infect (2007) 1.19
Declining incidence of imported malaria in the Netherlands, 2000-2007. Malar J (2010) 1.15
IL-12Rβ1 deficiency: mutation update and description of the IL12RB1 variation database. Hum Mutat (2013) 1.15
The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator? Malar J (2010) 1.15
Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One (2011) 1.15
Comparison of Mantoux and QuantiFERON TB Gold tests for diagnosis of latent tuberculosis infection in Army personnel. Clin Vaccine Immunol (2007) 1.14
Follow-up study of tuberculosis-exposed supermarket customers with negative tuberculin skin test results in association with positive gamma interferon release assay results. Clin Vaccine Immunol (2007) 1.14
Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol (2004) 1.14
Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. J Neurosurg (2006) 1.13
Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J Virol (2003) 1.11
Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis (Edinb) (2007) 1.08
ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis (2005) 1.08
Use of enzyme-linked immunospot assay with Mycobacterium tuberculosis-specific peptides for diagnosis of recent infection with M. tuberculosis after accidental laboratory exposure. J Clin Microbiol (2006) 1.07
Negative pressure wound treatment with polyvinyl alcohol foam and polyhexanide antiseptic solution instillation in posttraumatic osteomyelitis. Wound Repair Regen (2009) 1.05
Responses to reactive oxygen intermediates and virulence of Salmonella typhimurium. Microbes Infect (2003) 1.05
Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis (2009) 1.05
Salmonella enterica serovar Typhimurium RamA, intracellular oxidative stress response, and bacterial virulence. Infect Immun (2004) 1.05
Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. Br J Haematol (2005) 1.05
Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis (2009) 1.04
Maggot excretions/secretions are differentially effective against biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother (2007) 1.04
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis (2012) 1.04
PGC-1alpha is a key regulator of glucose-induced proliferation and migration in vascular smooth muscle cells. PLoS One (2009) 1.04
Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int (2004) 1.04
Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J (2006) 1.03
Salmonella gene rma (ramA) and multiple-drug-resistant Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother (2004) 1.03
Bacterial meningitis caused by the use of ventricular or lumbar cerebrospinal fluid catheters. J Neurosurg (2005) 1.02
Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine (2013) 1.02
Genetic variations in the interleukin-12/interleukin-23 receptor (beta1) chain, and implications for IL-12 and IL-23 receptor structure and function. Immunogenetics (2003) 1.02
A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis (2007) 1.00
Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS One (2011) 1.00
Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol (2004) 1.00
Risk factors for bacteremia with uropathogen not cultured from urine in adults with febrile urinary tract infection. Clin Infect Dis (2010) 1.00
Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis (2011) 1.00
Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin Exp Ophthalmol (2005) 1.00
Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun (2003) 1.00
Genetic characterization of measles viruses in China, 2004. Virol J (2008) 0.99
Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin Investig Drugs (2002) 0.99
The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis (2011) 0.99
Molecular complementation of IL-12Rbeta1 deficiency reveals functional differences between IL-12Rbeta1 alleles including partial IL-12Rbeta1 deficiency. Hum Mol Genet (2005) 0.99
Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. Eur J Immunol (2003) 0.99
Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. Lancet Infect Dis (2012) 0.99
Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics (2011) 0.99
IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine (2005) 0.99
IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12. Int Immunol (2008) 0.99
Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator. PLoS Pathog (2011) 0.98
Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol (2005) 0.97
Analysis of hepatitis C virus/classical swine fever virus chimeric 5'NTRs: sequences within the hepatitis C virus IRES are required for viral RNA replication. J Gen Virol (2003) 0.97
The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect (2010) 0.97
Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer (2002) 0.97
IL-23 and IL-12 responses in activated human T cells retrovirally transduced with IL-23 receptor variants. Mol Immunol (2008) 0.96
First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin (2010) 0.96
Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev (2015) 0.96
CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells. Eur J Immunol (2013) 0.96
Association of polymorphisms in IL-12/IFN-gamma pathway genes with susceptibility to pulmonary tuberculosis in Indonesia. Tuberculosis (Edinb) (2007) 0.96